Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.

Farrington CC, Yuan E, Mazhar S, Izadmehr S, Hurst L, Allen-Petersen BL, Janghorban M, Chung E, Wolczanski G, Galsky M, Sears R, Sangodkar J, Narla G.

J Biol Chem. 2020 Jan 17;295(3):757-770. doi: 10.1074/jbc.RA119.011443. Epub 2019 Dec 10.


Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.

O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, Brautigan DL, Haider S, Jackson M, Narla G.

Oncogene. 2020 Jan;39(3):703-717. doi: 10.1038/s41388-019-1012-2. Epub 2019 Sep 20.


The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.

Taylor SE, O'Connor CM, Wang Z, Shen G, Song H, Leonard D, Sangodkar J, LaVasseur C, Avril S, Waggoner S, Zanotti K, Armstrong AJ, Nagel C, Resnick K, Singh S, Jackson MW, Xu W, Haider S, DiFeo A, Narla G.

Cancer Res. 2019 Aug 15;79(16):4242-4257. doi: 10.1158/0008-5472.CAN-19-0218. Epub 2019 May 29.


Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.

Tohmé R, Izadmehr S, Gandhe S, Tabaro G, Vallabhaneni S, Thomas A, Vasireddi N, Dhawan NS, Ma'ayan A, Sharma N, Galsky MD, Ohlmeyer M, Sangodkar J, Narla G.

JCI Insight. 2019 Feb 21;4(4). pii: 125693. doi: 10.1172/jci.insight.125693. eCollection 2019 Feb 21.


Targeting PP2A in cancer: Combination therapies.

Mazhar S, Taylor SE, Sangodkar J, Narla G.

Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):51-63. doi: 10.1016/j.bbamcr.2018.08.020. Epub 2018 Sep 1. Review.


Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts.

Noto FK, Adjan-Steffey V, Tong M, Ravichandran K, Zhang W, Arey A, McClain CB, Ostertag E, Mazhar S, Sangodkar J, DiFeo A, Crawford J, Narla G, Jamling TY.

Mol Cancer Ther. 2018 Nov;17(11):2481-2489. doi: 10.1158/1535-7163.MCT-18-0156. Epub 2018 Sep 11.


PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. doi: 10.1126/scitranslmed.aaq1093.


The impact of phosphatases on proliferative and survival signaling in cancer.

Narla G, Sangodkar J, Ryder CB.

Cell Mol Life Sci. 2018 Aug;75(15):2695-2718. doi: 10.1007/s00018-018-2826-8. Epub 2018 May 3. Review.


Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.

McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD.

Cancer Res. 2018 Apr 15;78(8):2065-2080. doi: 10.1158/0008-5472.CAN-17-0123. Epub 2018 Jan 22.


Therapeutic targeting of PP2A.

O'Connor CM, Perl A, Leonard D, Sangodkar J, Narla G.

Int J Biochem Cell Biol. 2018 Mar;96:182-193. doi: 10.1016/j.biocel.2017.10.008. Epub 2017 Oct 26. Review.


Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.

Wiredja DD, Ayati M, Mazhar S, Sangodkar J, Maxwell S, Schlatzer D, Narla G, Koyutürk M, Chance MR.

Proteomics. 2017 Nov;17(22). doi: 10.1002/pmic.201700214. Epub 2017 Oct 25. Erratum in: Proteomics. 2018 Dec;18(24):e1870214.


Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.

Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma'ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G.

J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548. Epub 2017 May 15.


Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534].

Kastrinsky DB, Sangodkar J, Zaware N, McClinch K, Farrington CC, Giannini HM, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M.

Bioorg Med Chem. 2015 Dec 1;23(23):7487. doi: 10.1016/j.bmc.2015.11.002. Epub 2015 Nov 9. No abstract available.


All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.

Sangodkar J, Farrington CC, McClinch K, Galsky MD, Kastrinsky DB, Narla G.

FEBS J. 2016 Mar;283(6):1004-24. doi: 10.1111/febs.13573. Epub 2015 Nov 14. Review.


Reengineered tricyclic anti-cancer agents.

Kastrinsky DB, Sangodkar J, Zaware N, Izadmehr S, Dhawan NS, Narla G, Ohlmeyer M.

Bioorg Med Chem. 2015 Oct 1;23(19):6528-34. doi: 10.1016/j.bmc.2015.07.007. Epub 2015 Sep 11.


Bisphosphonates inactivate human EGFRs to exert antitumor actions.

Yuen T, Stachnik A, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Bailey J, Latif Y, Mujtaba S, Epstein S, Davies TF, Bian Z, Zallone A, Aggarwal AK, Haider S, New MI, Sun L, Narla G, Zaidi M.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17989-94. doi: 10.1073/pnas.1421410111. Epub 2014 Dec 1.


Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.

Stachnik A, Yuen T, Iqbal J, Sgobba M, Gupta Y, Lu P, Colaianni G, Ji Y, Zhu LL, Kim SM, Li J, Liu P, Izadmehr S, Sangodkar J, Scherer T, Mujtaba S, Galsky M, Gomez J, Epstein S, Buettner C, Bian Z, Zallone A, Aggarwal AK, Haider S, New MI, Sun L, Narla G, Zaidi M.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):17995-8000. doi: 10.1073/pnas.1421422111. Epub 2014 Dec 1.


Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors.

Das TK, Sangodkar J, Negre N, Narla G, Cagan RL.

Oncogene. 2013 Jun 27;32(26):3184-97. doi: 10.1038/onc.2012.326. Epub 2012 Aug 13.


Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.

Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, Burstein D, Zhang D, Politi K, Difeo A, Narla G.

J Clin Invest. 2012 Jul;122(7):2637-51. doi: 10.1172/JCI62058. Epub 2012 Jun 1.


Lung adenocarcinoma: lessons in translation from bench to bedside.

Sangodkar J, Katz S, Melville H, Narla G.

Mt Sinai J Med. 2010 Nov-Dec;77(6):597-605. doi: 10.1002/msj.20226. Review.


KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model.

Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, Martignetti JA.

Cancer Res. 2009 Jun 1;69(11):4733-41. doi: 10.1158/0008-5472.CAN-08-4282. Epub 2009 May 12.


Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.

Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, Terzo EA, Choudhri A, Narla G.

Lung Cancer. 2009 Dec;66(3):292-7. doi: 10.1016/j.lungcan.2009.02.014. Epub 2009 Mar 28.


Functional role of the KLF6 tumour suppressor gene in gastric cancer.

Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G.

Eur J Cancer. 2009 Mar;45(4):666-76. doi: 10.1016/j.ejca.2008.11.009. Epub 2008 Dec 26.


KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA.

J Clin Invest. 2008 Aug;118(8):2711-21. doi: 10.1172/JCI34780.

Supplemental Content

Loading ...
Support Center